Remaining on preventive antiplatelet therapy with aspirin significantly increases the risk of bleeding complications in patients undergoing partial nephrectomy, according to research presented at the European Association of Urology annual congress in Madrid, Spain.
Other products featured include a spacer system to protect men undergoing PCa radiotherapy, a pelvic floor exercise app, and more.
Two case studies of stereotactic ablative radiation therapy yielded survival times comparable to those seen with surgical treatment.
Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.
Two angiogenesis inhibitors that are widely used in metastatic renal cell carcinoma did not improve survival compared with placebo when used as adjuvant treatment, a new study found.
A novel optical imaging technology is showing promise as a potential diagnostic tool for renal cell carcinoma.
New, large-scale studies on active surveillance, IMRT complications, and robotic versus open prostatectomy were among the highlights of this year’s Genitourinary Cancers Symposium.
If further work with irreversible electroporation refines its capacity for discrete tissue ablation deep within the kidney and adjacent to large blood vessels, and especially if larger tumors can be addressed, then this would be a major step forward in the minimally invasive treatment of localized renal cancer.
Percutaneous irreversible electroporation is showing promise as a novel minimally invasive approach for treating small renal tumors, according to the experience of urologists at the University of Texas Southwestern Medical Center, Dallas.
Urologists at the University of Southern California’s Institute of Urology in Los Angeles are taking robotic kidney surgery to a new level. Inderbir S. Gill, MD, MCh, executive director of the USC Institute of Urology, has pioneered the use of the robot in patients with complex (level III) inferior vena cava thrombi.
New products and services from Samsung Electronics America, Syneron Medical, American Medical Systems, New Star, Buffalo Filter, Cook Medical, Endo International, Trimel BioPharma Metamark, and the National Comprehensive Cancer Network.
In this interview, Arie Belldegrun, MD, discusses the benefits of cancer immunotherapy, the importance of a multidisciplinary treatment approach, and what the future holds for this treatment.
Drugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.
Olympus has announced the FDA 510(k) clearance of Narrow Band Imaging as enabling effective targeting of biopsies not seen under white light and improved visualization of tumor margins in nonmuscle-invasive bladder cancer.
Kidney cancer patients were more likely to undergo partial nephrectomy when treated in hospitals that were early adopters of robotic surgery, according to a recent report that one leading expert calls “some of the best evidence to date of a favorable impact of surgical robots in urologic care.”
Other products discussed in this article include a prosthesis for underactive bladder, a prostate cancer test, and an erectile dysfunction drug.
Blue light cystoscopy with hexaminolevulinate HCl (HAL-BLC) should be considered for initial diagnosis of nonmuscle-invasive bladder cancer, an expert panel of urologists recently concluded.
Survivors of bladder, kidney, and two other forms of cancer who smoked 20 or more cigarettes a day prior to their cancer diagnoses have an up to fivefold higher risk of developing a second smoking-associated cancer compared to survivors of the same cancers who never smoked.
Other products featured include a 16-slice CT scanner, new generic testosterone gel, prostate cancer risk calculator, and more.
Research on the quality of bladder biopsy and bladder cancer survival point to problems of suboptimal biopsies and incorrect tumor staging, researchers say.
Drugs and devices in the pipeline from Repros Therapeutics, Bavarian Nordic, NxThera, Solace Therapeutics, Generex Biotechnology, Bioniche, OncoCyte, HistoSonics, and Pacific Edge.
Other products featured include a testosterone gel, exercise program to strengthen male pelvic muscles, and a book about prostate cancer diagnosis and management.
Drugs and devices in the pipeline form Clarus Therapeutics, Nymox Pharmaceutical, Bioniche Life Sciences, Repros Therapeutics, BioLight Life Sciences Investments/Micromedic Technologies, Cubist Pharmaceuticals, Takeda Pharmaceutical, H. Lundbeck A/S, Transplant Genomics, Orion, Bayer, and Roche.
In our “Best of AUA” report, Urology Times’ editors and writers present the AUA annual meeting’s take-home messages in 15 therapeutic areas.
Philippe E. Spiess, MD, MS, presents the take home messages on penile, testis, and urethral cancer from the AUA annual meeting in Orlando, FL.
